EcoDrugPlus

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSBTAG00000010163
Gene Symbol: SCNN1G
6 Enzyme and pathways 5 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSBTAG00000018520
Gene Symbol: SCN1A
3 Enzyme and pathways 5 Cross references
153 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSBTAG00000046911
Gene Symbol: SCN10A
5 Cross references
314 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSBTAG00000017174
Gene Symbol: SCN11A
3 Enzyme and pathways 5 Cross references
108 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSBTAG00000038180
Gene Symbol: SCN2A
5 Cross references
142 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSBTAG00000019385
Gene Symbol: SCN3A
3 Enzyme and pathways 5 Cross references
144 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSBTAG00000004770
Gene Symbol: SCN4A
5 Cross references
204 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSBTAG00000009155
Gene Symbol: SCN5A
3 Enzyme and pathways 5 Cross references
106 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSBTAG00000019137
Gene Symbol: SCN7A
5 Cross references
98 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSBTAG00000021339
Gene Symbol: SCN8A
3 Enzyme and pathways 5 Cross references
288 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSBTAG00000002425
Gene Symbol: SCN9A
3 Enzyme and pathways 5 Cross references
122 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSBTAG00000005925
Gene Symbol: SLC10A2
5 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).